Simultaneous determination of etoposide and its catechol metabolite in the plasma of pediatric patients by liquid chromatography/tandem mass spectrometry
- 20 July 2001
- journal article
- research article
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 36 (7) , 771-781
Abstract
The anticancer drug etoposide is associated with leukemias with MLL gene translocations and other translocations as a treatment complication. The genotype of cytochrome P450 3A4 (CYP3A4), which converts etoposide to its catechol metabolite, influences the risk. In order to perform pharmacokinetic studies aimed at further elucidation of the translocation mechanism, we have developed and validated a liquid chromatography/electrospray/tandem mass spectrometry assay for the simultaneous analysis of etoposide and its catechol metabolite in human plasma. The etoposide analog teniposide was used as the internal standard. Liquid chromatography was performed on a YMC ODS‐AQ column. Simultaneous determination of etoposide and its catechol metabolite was achieved using a small volume of plasma, so that the method is suitable for pediatric patients. The limits of detection were 200 ng ml−1 etoposide and 10 ng ml−1 catechol metabolite in human plasma and 25 ng ml−1 etoposide and 2.5 ng ml−1 catechol metabolite in protein‐free plasma, respectively. Acceptable precision and accuracy were obtained for concentrations in the calibration curve ranges 0.2–100 µg ml−1 etoposide and 10–5000 ng ml−1 catechol metabolite in human plasma. Acceptable precision and accuracy for protein‐free human plasma in the range 25–15 000 ng ml−1 etoposide and 2.5–1500 ng ml−1 etoposide catechol were also achieved. This method was selective and sensitive enough for the simultaneous quantitation of etoposide and its catechol as a total and protein‐free fraction in small plasma volumes from pediatric cancer patients receiving etoposide chemotherapy. A pharmacokinetic model has been developed for future studies in large populations. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 30 references indexed in Scilit:
- Etoposide Metabolites Enhance DNA Topoisomerase II Cleavage near Leukemia-Associated MLL Translocation BreakpointsBiochemistry, 2001
- Substrates of human hepatic cytochrome P450 3A4Toxicology, 1995
- Catalytic function of DNA topoisomerase IIBioEssays, 1991
- EtoposideDrugs, 1990
- Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposideBiochemistry, 1989
- Mechanism of Action of Antitumor Drug Etoposide: A ReviewJNCI: Journal of the National Cancer Institute, 1988
- Pharmacokinetics of Anticancer Drugs in ChildrenClinical Pharmacokinetics, 1987
- In vitro metabolism of etoposide (VP-16-213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteinsBiochemical Pharmacology, 1987
- Inactivation of φX174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213European Journal of Cancer and Clinical Oncology, 1985
- High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical DetectionJournal of Pharmaceutical Sciences, 1984